# OnCo record xencor (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/xencor/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "xencor" ;
  schema:name "Xencor"@en ;
  schema:description "Xencor is an antibody-engineering company (XmAb Fc technology) developing 2+1 T-cell engagers for kidney cancer (ENPP3) and ovarian/germ-cell tumours (CLDN6)."@en ;
  schema:url <https://onco.cc/companies/xencor/>, <https://xencor.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://investors.xencor.com/news-releases/news-release-details/xencor-highlights-corporate-priorities-and-2026-pipeline> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/ovarian/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/cd3/> ;
  onco:drugs <https://onco.cc/drugs/vudalimab/> .